Business
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceutica...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference ParticipationToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization of GRAFAPEX™ (treosulfan) for Injection in the United States and on certain recent capital allocation and capital structure developments and announced company management's participation in two upcoming investor conferences. All dollar amounts in this news release are in US dollars unless specified otherwise.GRAFAPEX updateCommercialization progress on GRAFAPEX as of March 31, 2026 included the following operational highlights:As of March 31, 2026, 56 individual healthcare institutions (December 31, 2025 - 46), representing 31% of the 180 transplant centers in the United States (December 31, 2025 - 26%), have made positive formulary inclusion determinations.Wholesaler data as of March 31, 2026 shows that 64 of the 180 transplant centers have already ordered GRAFAPEX for procedures in their institutions (December 31, 2025 - 55).These operating indicators are consistent with the expected product-level performance of GRAFAPEX described by Medexus in connection with its fiscal Q3 2026 results. Medexus expects to provide additional information regarding the ongoing GRAFAPEX commercialization and related financial performance in connection with the reporting of its fiscal year 2026 results, which is expected to occur in June.Medexus remains encouraged by the trajectory of the commercialization efforts for GRAFAPEX in the United States, and believes it supports Medexus's expectation that annual product-level net revenue from GRAFAPEX will exceed $100 million within five years after commercial launch, as further described in Medexus's filings with the Canadian securities regulatory authorities.\"As previously disclosed, Medexus had identified fiscal Q4 2026 as an important quarter in the expected GRAFAPEX commercialization trajectory,\" commented Ken d'Entremont, Chief Executive Officer of Medexus. \"These operating indicators as of March 31 are consistent with our previously disclosed expectations that GRAFAPEX will be accretive to quarterly operating cash flows starting in the just-completed calendar...